News Related to Expanded Disability Status Scale

Related coverage linked through entity extraction aliases.

Daratumumab Shows Promise in NMOSD as FDA Accepts Iberdomide NDA for Multiple Myeloma

May 02, 2026

Phase 3 trial data show daratumumab reduced relapse risk by 74% in NMOSD. Separately, the FDA accepted an NDA for iberdomide plus daratumumab/dexamethasone in relapsed/refractory multiple myeloma, with a PDUFA date of August 17, 2026.

Fenebrutinib Shows 12% Reduction in Disability Progression vs Ocrelizumab in PPMS Trial

Feb 25, 2026

Phase III FENtrepid trial results show investigational BTK inhibitor fenebrutinib met its primary endpoint of non-inferiority to ocrelizumab in primary progressive MS, with a 12% reduction in disability progression risk and strongest effect on upper limb function.